Mr. Waxman (for himself, Mr. Berry, Mr. Stark, Mr. Brown of Ohio, and Mr. Deutsch) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned
To ensure the timely availability of generic drugs through enhancement of drug approval and antitrust laws enforced by the Food and Drug Administration and the Federal Trade Commission regarding brand name drugs and generic drugs.
Citations are generated automatically from bibliographic data as a convenience and may not be complete or accurate.
Chicago
U.S. Congress. House. Prescription Drug Competition Act of 2001. H.R. 1530. 107th
Cong., 1st
sess., Introduced in House April 4, 2001. https://www.govinfo.gov/app/details/BILLS-107hr1530ih.
APA
Congress, House of Representatives (2001, April 4). Prescription Drug Competition Act of 2001 (H.R. 1530 (IH)). Retrieved from https://www.govinfo.gov/app/details/BILLS-107hr1530ih.
MLA
United States, Congress, House of Representatives. Prescription Drug Competition Act of 2001. U.S. Government Publishing Office, https://www.govinfo.gov/app/details/BILLS-107hr1530ih. 107th Congress, H.R. 1530, Introduced in House 4 Apr. 2001.
Bluebook
H.R.1530 - 107th Congress (2001-2002): Prescription Drug Competition Act of 2001, H.R.1530, 107th Cong. (2001), https://www.govinfo.gov/app/details/BILLS-107hr1530ih.
